Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in
combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to
evaluate safety and tolerability of this combination at that dose.